PAREMA PArtial REbreathing for Migraine with Aura
- Coordinator
- Rehaler AS, Denmark
- Runs
- 1 November 2023 to 31 October 2025
- Status
- Ended early
- EU funding
- €1.5m
- Total cost
- €2.1m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190133087
What the project is doing
In the project's own words, from its summary on CORDIS.
Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life. Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential. The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system.
The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability. To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Rehaler AS | Aarhus C | Denmark | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI